Cargando…
Competing risks determining event-free survival in early breast cancer.
To evaluate the natural history of a disease and the effects of therapeutic interventions, it is important to determine which are the causes of treatment failure and to assess the extent to which each cause contributes to the total failure rate. The paper presents a new biostatistical technique to d...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977968/ https://www.ncbi.nlm.nih.gov/pubmed/1419642 |
_version_ | 1782135376181198848 |
---|---|
author | Arriagada, R. Rutqvist, L. E. Kramar, A. Johansson, H. |
author_facet | Arriagada, R. Rutqvist, L. E. Kramar, A. Johansson, H. |
author_sort | Arriagada, R. |
collection | PubMed |
description | To evaluate the natural history of a disease and the effects of therapeutic interventions, it is important to determine which are the causes of treatment failure and to assess the extent to which each cause contributes to the total failure rate. The paper presents a new biostatistical technique to decompose the total event-free survival of a diseased population into cause-specific failure rates. The technique was based on a competing risk approach thereby avoiding biases related to assumptions of independence between different types of event. Such assumptions are inherent in the conventional Kaplan-Meier or actuarial methods. The competing risk method was used to analyse the pattern of failure among 2,850 pre- and postmenopausal patients with early-stage breast cancer and the results were compared to those obtained using conventional methods. The following events were analysed: loco-regional recurrence, distant metastasis, contralateral breast cancer, other new primary malignancies, and intercurrent deaths. The rate of new primary malignancies was found to be significantly higher in post- than in premenopausal patients (6% vs 3% at 10 years). In low-risk, node-negative postmenopausal patients the incidence of recurrences from breast cancer were found to be no greater than other types of events. This observation highlights the significance of the effect of different adjuvant therapies not only on the disease itself but also on the risk of second primary malignancies and other intercurrent diseases. In general, it was found that the conventional statistical methods tended to overestimate the event-specific rates. In conclusion, the method based on competing risks permits an unbiased analysis of all types of events determining the total event-free survival. It is thus useful for the description of the natural history of breast cancer as well as other diseases. |
format | Text |
id | pubmed-1977968 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1992 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19779682009-09-10 Competing risks determining event-free survival in early breast cancer. Arriagada, R. Rutqvist, L. E. Kramar, A. Johansson, H. Br J Cancer Research Article To evaluate the natural history of a disease and the effects of therapeutic interventions, it is important to determine which are the causes of treatment failure and to assess the extent to which each cause contributes to the total failure rate. The paper presents a new biostatistical technique to decompose the total event-free survival of a diseased population into cause-specific failure rates. The technique was based on a competing risk approach thereby avoiding biases related to assumptions of independence between different types of event. Such assumptions are inherent in the conventional Kaplan-Meier or actuarial methods. The competing risk method was used to analyse the pattern of failure among 2,850 pre- and postmenopausal patients with early-stage breast cancer and the results were compared to those obtained using conventional methods. The following events were analysed: loco-regional recurrence, distant metastasis, contralateral breast cancer, other new primary malignancies, and intercurrent deaths. The rate of new primary malignancies was found to be significantly higher in post- than in premenopausal patients (6% vs 3% at 10 years). In low-risk, node-negative postmenopausal patients the incidence of recurrences from breast cancer were found to be no greater than other types of events. This observation highlights the significance of the effect of different adjuvant therapies not only on the disease itself but also on the risk of second primary malignancies and other intercurrent diseases. In general, it was found that the conventional statistical methods tended to overestimate the event-specific rates. In conclusion, the method based on competing risks permits an unbiased analysis of all types of events determining the total event-free survival. It is thus useful for the description of the natural history of breast cancer as well as other diseases. Nature Publishing Group 1992-11 /pmc/articles/PMC1977968/ /pubmed/1419642 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Arriagada, R. Rutqvist, L. E. Kramar, A. Johansson, H. Competing risks determining event-free survival in early breast cancer. |
title | Competing risks determining event-free survival in early breast cancer. |
title_full | Competing risks determining event-free survival in early breast cancer. |
title_fullStr | Competing risks determining event-free survival in early breast cancer. |
title_full_unstemmed | Competing risks determining event-free survival in early breast cancer. |
title_short | Competing risks determining event-free survival in early breast cancer. |
title_sort | competing risks determining event-free survival in early breast cancer. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977968/ https://www.ncbi.nlm.nih.gov/pubmed/1419642 |
work_keys_str_mv | AT arriagadar competingrisksdeterminingeventfreesurvivalinearlybreastcancer AT rutqvistle competingrisksdeterminingeventfreesurvivalinearlybreastcancer AT kramara competingrisksdeterminingeventfreesurvivalinearlybreastcancer AT johanssonh competingrisksdeterminingeventfreesurvivalinearlybreastcancer |